Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferriprox (deferiprone) vs deferoxamine for treatment of iron overload in sickle cell disease and other anemias
2013-002181-39Phase 3Terminated
- Sponsor
- ApoPharma Inc.
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of deferiprone in iron overload, sickle cell disease (SCD) and anaemia (2 arms), sponsored by ApoPharma Inc. Primary endpoint: Change in liver iron concentration by MRI at Week 52. Started Oct 2013; status: terminated.
02
Drugs
deferiprone
03
Conditions
iron overloadsickle cell disease (SCD)anaemia
Beyond the preview
Go deeper on 2013-002181-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002181-39.